Inovio Pharmaceuticals specializes in DNA-based immunotherapies for HPV-related conditions, cancer, and infectious diseases. The company's flagship drug, INO-3107, shows promise for treating recurrent ...
(RTTNews) - Today's Daily Dose brings you news about the expanding footprint of Apyx Medical's Helium Plasma Technology products; Inovio securing a $71 million funding from the U.S. Department of ...
Shares of Inovio Pharmaceuticals INO jumped 20.6% on Wednesday after the FDA agreed to the company’s rolling submission timeline for the biologics license application (BLA) seeking approval for ...
Inovio Pharmaceuticals (INO) reported a disappointing 3Q25 with a GAAP EPS loss of -$0.87, missing consensus by $0.45 and triggering a 12% stock slide. INO ended the quarter with $50.8 million in cash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results